Tissue Regenix Group PLC UK distribution partner for OrthoPure(R) XT (9371W)
August 24 2020 - 2:00AM
UK Regulatory
TIDMTRX
RNS Number : 9371W
Tissue Regenix Group PLC
24 August 2020
Tissue Regenix Group plc
UK distribution partner for OrthoPure(R) XT
Leeds, UK, 24 August 2020 - Tissue Regenix Group (AIM:TRX)
("Tissue Regenix" or the "Group"), the regenerative medical devices
company, announces it has entered into a distribution agreement and
secured its first order with a speciality supplier of orthopaedic
and biologic products, for the UK distribution of OrthoPure(R) XT,
following its recent CE Mark approval in June 2020.
OrthoPure(R) XT is a decellularized porcine tendon, developed
using the Group's patented dCELL(R) technology. It was granted CE
Mark approval for the reconstruction of knee ligaments to restore
knee function and stability.
Under the terms of this UK distribution agreement, the NHS and
private healthcare sectors will have access to OrthoPure(R) XT. The
Group will initially focus on commercialisation of OrthoPure(R) XT
in the UK before commencing a gradual roll-out into certain other
European countries over time.
The Group has received the first modest order and delivery is
expected to take place during Q4 2020. It is expected that demand
for this product line will increase in 2021 as additional
distribution opportunities are identified.
Gareth Jones, Interim Chief Executive Office of Tissue Regenix
Group plc, commented:
"As a specialist supplier of orthopaedic and biologic products
to the NHS, we have secured an ideal partner to support the
commercialisation of OrthoPure(R) XT in the UK. We believe
OrthoPure(R) XT has the potential to be a disruptive product in the
market for reconstruction of knee ligaments and offers benefits to
patients and healthcare providers. The launch of OrthoPure(R) XT is
a key milestone for the Company as we continue to strengthen our
product portfolio."
For more Information:
Tissue Regenix Group plc
Caitlin Pearson, Head of Communications Tel: 0330 430 3073
------------------------------------------- ---------------------
Stifel Nicolaus Europe Limited (Nominated Tel: 0207 710 7600
Adviser and Broker)
Ben Maddison / Alex Price
------------------------------------------- ---------------------
FTI Consulting Tel: 0203 727 1000
Simon Conway / Victoria Foster Mitchell /
Mary Whittow
=========================================== =====================
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTUSAVRRUUWURR
(END) Dow Jones Newswires
August 24, 2020 02:00 ET (06:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2024 to Jun 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2023 to Jun 2024